Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Front. Cell Dev. Biol.

Sec. Developmental Epigenetics

Volume 13 - 2025 | doi: 10.3389/fcell.2025.1549588

The role of m5C, m1A and m7G modifications in tumors of urinary system

Provisionally accepted
Wei  XueWei XueYuanyuan  ZhaoYuanyuan ZhaoGong  ZhangGong ZhangZhiyuan  LiZhiyuan LiJixin  LiJixin LiXiang  FeiXiang Fei*
  • Department of Urology, ShengJing Hospital of China Medical University, Shenyang, China

The final, formatted version of the article will be published soon.

Malignant tumors of the urinary system, such as kidney cancer, bladder cancer, and prostate cancer, remain a significant challenge despite the various treatment options available. Identifying therapeutic targets for urological tumors is crucial due to the potential for recurrence and metastasis. Recent research has highlighted the importance of RNA modifications in post-transcriptional regulation, impacting various biological functions in urological tumors, including tumorigenesis, progression, metastasis, and drug resistance. However, the specific mechanisms underlying these interactions are not fully understood. This review will focus on exploring the regulatory role of RNA modifications like m1A, m5C, and m7G in urological tumors, shedding light on the pathways and molecular mechanisms involved. This analysis aims to provide new insights for the treatment of urological tumors.

Keywords: RNA modification, m5C, m1A, m7G, Urological tumours

Received: 21 Dec 2024; Accepted: 16 Jul 2025.

Copyright: © 2025 Xue, Zhao, Zhang, Li, Li and Fei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Xiang Fei, Department of Urology, ShengJing Hospital of China Medical University, Shenyang, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.